Key Takeaways
- The Bank of England (BoE) maintained its benchmark interest rate at 3.75% in a 6-3 vote, despite warning that inflation is projected to rise above 4% by Q1 2027 due to persistent energy shocks.
- CoreWeave (CRWV) proposed a $3 billion convertible senior notes offering due 2033 to fund AI infrastructure expansion, alongside an at-the-market program to sell up to 35 million Class A shares.
- Novo Nordisk (NVO) entered a drug discovery partnership with Orbis Medicines worth up to $1.4 billion to develop oral macrocycle therapeutics for cardiometabolic diseases.
- The BoE unveiled a long-term Quantitative Tightening (QT) plan to reduce its gilt stock by £368 billion by 2034, involving annual sales of £20 billion to the government.
- ECB Governing Council member Olli Rehn noted that while the euro area was previously in a "good place" on inflation, recent shocks mean the situation has shifted, though energy price spikes have not yet triggered a wage-price spiral.
Bank of England Holds Rates as Inflation Risks Mount
The Bank of England opted to keep interest rates steady at 3.75% on Thursday, marking the sixth consecutive meeting without a change. The decision was not unanimous, as policymakers Huw Pill, Megan Greene, and Catherine Mann voted for a 25-basis-point hike to 4%, citing the need to pre-empt second-round inflationary effects. Governor Andrew Bailey cautioned that while evidence of such effects remains limited, policy may need to tighten if the ongoing conflict in the Middle East continues to drive energy costs higher.
The central bank significantly revised its outlook, now projecting UK inflation to peak slightly above 4% in the first quarter of 2027. This hawkish tilt led traders to price in approximately 38 basis points of additional hikes by the end of the year. The BoE also confirmed it will pause its Asset Purchase Facility (APF) gilt auctions until April 2027, shifting toward a strategy of selling gilts directly to the government rather than the open market to minimize market volatility.
CoreWeave Launches Multi-Billion Dollar Capital Raise
AI cloud provider CoreWeave (CRWV) announced a massive capital-raising initiative to support its aggressive data center expansion. The company plans to offer $3 billion in convertible senior notes due 2033 in a private placement, with an option for initial purchasers to buy an additional $500 million. Simultaneously, CoreWeave established an at-the-market (ATM) equity program allowing for the sale of up to 35 million Class A shares, which would be worth approximately $2.9 billion based on recent trading prices.
The fundraising follows a period of explosive growth for the company, which recently reported a revenue backlog of $104.2 billion, up 246% year-over-year. Proceeds from the offerings are earmarked for general corporate purposes, including the repayment of existing debt and capital expenditures for AI infrastructure. CoreWeave’s stock has seen significant volatility as it transitions from a high-leverage survival phase to a scaling growth phase backed by major contracts with firms like Meta Platforms (META).
Novo Nordisk Expands Cardiometabolic Pipeline
Novo Nordisk (NVO) has solidified its lead in the cardiometabolic space by signing a strategic collaboration with Orbis Medicines. The deal, valued at up to $1.4 billion, focuses on using Orbis's AI-enabled "nGen" platform to discover oral macrocycle therapeutics. These "biologics-in-a-pill" aim to replace traditional injectable treatments for obesity and heart disease, potentially offering higher patient compliance and lower production costs.
Under the agreement, Orbis will receive upfront payments and is eligible for development and commercial milestones, plus tiered royalties. Novo Nordisk will also make a direct strategic investment in the Copenhagen-based biotech. This move comes as Novo—which recently underwent a corporate rebrand to simply "Novo"—seeks to diversify its portfolio beyond its blockbuster Wegovy and Ozempic brands amid increasing competition from Eli Lilly (LLY).
ECB Signals Shifting Inflation Landscape
In Europe, ECB Governing Council member Olli Rehn provided a nuanced update on the Eurozone's inflation trajectory. Rehn stated that while the central bank was previously satisfied with the disinflationary trend, the "latest shocks"—primarily energy-related—have altered the landscape. Despite these pressures, he emphasized that wage growth remains moderate and that a feared price-wage spiral has not yet materialized.
The comments follow the ECB's decision last week to raise its deposit rate to 2.50%. Markets are currently monitoring for signs of further tightening in October, as new staff projections show headline inflation averaging 3.0% in 2026 and remaining above the 2% target through 2028. Rehn’s colleague, Gabriel Makhlouf, added that every upcoming meeting remains "live," suggesting the ECB is prepared to act if energy shocks begin to seep into core inflation.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.